• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

miRNA Research and Diagnostics Markets: Forecast to 2019

$995.00 – $1,990.00

Clear
SKU: KLI5332151 Category: Biotechnology Market Research Pages: 200
  • Description
  • Table of Contents
  • Latest reports

Description

miRNA Research and Diagnostics Markets

This report, miRNA Research and Diagnostic Markets, focuses on the test product potential of microRNA. These pieces of RNA are seen as important regulators of gene expression; including growth, form, differentiation, and apoptosis. They serve myriad functions as regulator molecules in post-transcriptional gene silencing.

As the study details, a wide range of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.

As part of its coverage of this topic, this report includes the following:

  • Discussion of miRNAs
  • Upside for miRNA Diagnostic Technologies
  • Downside Factors
  • miRNAs and Neurological Disorders
  • Prostate Cancer Screening and miRNAs
  • miRNAs and Resistance to Anti-Cancer Drugs
  • Theoretical Limitations
  • Discussion of Patent Issues
  • Interviews with Industry Experts
  • Market Size
  • miRNA and Metastatic Brain Lesions

As part of its coverage, the miRNA offerings and products in developments in the following companies are extensively reviewed:

  • Illumina, Inc.
  • Isis Pharmaceuticals
  • Mello Biotechnology Inc.
  • Microlin Bio
  • MiRagen Therapeutics
  • MiRNA Therapeutics
  • Agilent Technologies
  • Alnylam
  • AMSBIO
  • Applied Biosystems
  • Asuragen
  • DiamiR, LLC
  • Novartis
  • Pacific Edge Biotechnology
  • Prolias Technologies
  • Regulus Therapeutics
  • Rosetta Genomics
  • Santaris Pharma A/S
  • Sirnaomics, Inc.
  • Somagenics
  • Diagnostics: Small RNA Assays and Biomarker Validation
  • Tekmira Pharmaceuticals Corporation
  • Thermadiag
  • Thermo Fisher Scientific, Inc.
  • Dicerna
  • Eisai Biomarkers and Personalized Medicine
  • Diagnostics
  • Exiqon
  • Genomic Health Inc.
  • Gensignia
  • GlaxoSmithKline Discovery and Molecular Toxicology
  • Groove Biopharma (formerly Mirina)
  • Hologic-Gen Probe Inc

Table of Contents

  1. Executive Summary
  2. Introduction

2.1. Junk DNA: Is There Such a Thing?

2.2. An Animated Debate

2.3. RNA Molecules Regulate Gene Expression

2.4. Types of Non-coding RNAs

2.5. Types of Small RNAs

  1. Current State of the Art

3.1. A Game Changer for Improved Diagnosis

3.1.1. MicroRNAs Are a Factor in Many Diseases

3.1.2. miRNAs and Neurological Disorders

3.1.3. miRNA and Metastatic Brain Lesions

3.1.4. miRNA Involvement in Cancers Is Widespread

3.1.5. Prostate Cancer Screening and miRNAs

3.1.6. Bladder Cancer and MicroRNAs in Urine

3.1.7. Colorectal Cancer

3.1.8. miRNAs and Resistance to Anti-Cancer Drugs

3.2. MicroRNA Nomenclature

3.3. MicroRNA Biogenesis

3.4. MicroRNA Cellular Functions

3.5. MicroRNA and Other Diseases

3.5.1. How Are microRNAs Linked to Disease?

3.5.2. Circulating microRNAs as Disease Markers

3.5.3. miRNAs and Tissue Injury

3.5.4. The Exosome

3.6. Exploring Therapeutic Applications

3.6.1. A Cautionary Tale: The History of Antibody Development

3.6.2. A Mixed Assessment of miRNA Therapeutic Potential

  1. Companies Developing microRNA Diagnostic Technologies

4.1. Agilent Technologies

4.2. Alnylam

4.3. AMSBIO

4.4. Applied Biosystems

4.5. Asuragen

4.6. DiamiR, LLC

4.7. Dicerna

4.8. Eisai Biomarkers and Personalized Medicine

4.9. Diagnostics

4.10. Exiqon

4.11. Genomic Health Inc.

4.12 Gensignia

4.13. GlaxoSmithKline Discovery and Molecular Toxicology

4.14. Groove Biopharma (formerly Mirina)

4.15. Hologic-Gen Probe Inc.

4.16. Illumina, Inc.

4.17. Isis Pharmaceuticals

4.18. Luminex (Millipore)

4.19. Mello Biotechnology Inc.

4.20. Microlin Bio

4.21. MiRagen Therapeutics

4.22. MiRNA Therapeutics

4.23. Novartis

4.24. Pacific Edge Biotechnology

4.25. Prolias Technologies

4.26 Regulus Therapeutics

4.26.1. Biomarker Studies of miRNAs through the Application of Microarrays

4.26.2. Clinical Trials

4.27. Rosetta Genomics

4.28. Santaris Pharma A/S

4.29. Sirnaomics, Inc.

4.30. Somagenics

4.30.1. Diagnostics: Small RNA Assays and Biomarker Validation

4.31. Tekmira Pharmaceuticals Corporation

4.32. Thermadiag

4.33. Thermo Fisher Scientific, Inc.

  1. Market Estimates and Forecasts

5.1. Long Range Estimate

5.2. Negative Forces That Can Affect the Outlook for miRNA Diagnostic Technologies

5.2.1. Theoretical Limitations of miRNAs

5.2.2. Resistance to miRNA R&D on the Part of Big Pharma

5.2.3. Lack of Basic Science Support by Government Funding Agencies

5.2.4. Patent Issues

5.3. Positive Factors That Move the Estimates

5.3.1. Inherent Shortcomings of Competitive Detection Systems

5.3.2. miRNA Technological Improvements

5.3.3. Current Studies Are Encouraging

5.3.4. Availability of Venture Capital

5.3.5. Specific Venture Capital Funding Opportunities

  1. Interviews with Industry Experts: Biomarkers

6.1. Anton Wellstein MD, PhD

6.2. Kai Wang, PhD

6.3. Samuil R. Umansky, MD, PhD

6.4. Dr. Mustafa Ozen

6.5. Dr. Nader Rifai

  1. The Future of miRNA-Based Diagnostics

7.1. Future Perspectives

7.2. Summary Recommendations

7.2.1. MicroRNA Compares Well with Competing Technologies

7.2.2. MicroRNA Assessment, Based on Its Own Performance

7.2.3. A Nuanced Endorsement

LIST OF EXHIBITS

  1. Executive Summary

Table 1.1: Forms of RNA and Abbreviations Explained

  1. Introduction

Table 2.1: Different Classes of RNA Molecules

  1. Current State of the Art

Figure 3.1: Increasing Number of Publications on miRNA

Figure 3.2: Results of microRNA Microarray Analysis

Table 3.1: Colorectal Cancer-Associated miRNA Markers

Figure 3.3: Method Validation: miRNAs Associated with Prostate Cancer

Table 3.2: Verification of Known Tissue-Specific Expression Patterns of Three mRNAs as Markers of Tissue Injury (miR-122, miR-133a and miR-124 Concentrations in Nine Rat Tissues)

Figure 3.4: Exosomes

Figure 3.5: Lagging Rate of Therapeutic Antibody Approval

  1. Companies Developing microRNA Diagnostic Technologies

Figure 4.1: Biogenesis of microRNAs (Gensignia)

Table 4.1: Regulus’ Clinical Map Initiative Outlines Current Status of Its microRNA Therapeutics Pipeline

Figure 4.2: Natural microRNA Precursors Marketed by Mello Biotech

Table 4.2: Summary of Data from Regulus miRNA Assessment Study

  1. Market Estimates and Forecasts

Table 5.1: miRNA Testing Market

Table 5.2: Major Providers of miRNA Tools and Services

Table 5.3: Top 10 Pharmaceutical Companies by R&D Expenditures in 2013

Figure 5.1: Funding Trends for Basic Research, 1950-2019

Table 5.4: Some Venture Capital Funding Opportunities

 

    The Market for Single Cell Analysis in Genomics: Next-Generation Sequencing and Other Technology, 2023-2027
    April 3, 2023
    The World Market for Liquid Biopsy, 2023
    December 29, 2022
    The Market for RNA Sequencing, 2nd Edition
    September 7, 2022
    Single Cell Analysis Survey
    August 29, 2022

Related products

  • Placeholder image

    Protein Therapeutics Market – The Science and Business of a Growing Sector

    $995.00 – $7,800.00
  • Placeholder image

    U.S. Markets in Analytical Chip Technology: Gene, Protein, Tissue, Cell, and Microbiological Microarrays, 2nd Ed.

    $3,500.00 – $7,000.00
  • Placeholder image

    Glycosylated Protein Therapeutics – A Market Briefing

    $795.00 – $1,590.00
  • Placeholder image

    Wound Care Markets, 3rd. Edition, Vol. I – Skin Ulcers

    $2,995.00 – $5,990.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • New Kalorama Report Pegs Clinical Lab Services Market at 168BN May 18, 2023
  • WHO Reports Lowered Threat Level of COVID-19; What Does it Mean for Testing? May 9, 2023
  • SDi Releases Flagship Market Research Report on Analytical and Life Science Instruments: The Global Assessment Report May 3, 2023
  • Despite Declines, COVID-19 Still a Large IVD Market May 1, 2023
  • Single Cell Genomics Market Reaches $1 Billion April 27, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Biopharmaceutical and Vaccine Production Markets (Mammalian Cell Production,...Advanced Remote Patient Monitoring Systems, Forecasts to 2019, 7th Edition
Scroll to top